Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sinovac Biotech ( (SVA) ) just unveiled an update.
On June 18, 2025, Sinovac Biotech Ltd. announced a Special Meeting of Shareholders scheduled for July 8, 2025, to address critical governance issues, including the potential removal of the current Board and the election of new directors. The current Board, which has been in place for approximately 120 days, has declared a $55 per share dividend and plans further dividends, contrasting sharply with the previous board’s lack of dividend payments over seven years. The current Board is also working to resolve legal disputes and improve relations with NASDAQ, following a trading halt caused by past board actions.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a company operating in the biotechnology industry, primarily focused on the development, manufacturing, and commercialization of vaccines. The company is headquartered in Beijing, China, and has a significant market focus on providing vaccines for infectious diseases.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
For an in-depth examination of SVA stock, go to TipRanks’ Overview page.